RG
ALXO icon

Redmile Group’s ALX Oncology ALXO Stock Holding History

Redmile Group’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16M Buy
7,964,188
+4,699,470
+144% +$8.95M 1.06% 15
2025
Q4 		$3.69M Sell
3,264,718
-68,265
-2% -$103K 0.27% 31
2025
Q3 		$6.1M Sell
3,332,983
-58,472
-2% -$50.6K 0.59% 28
2025
Q2 		$1.41M Sell
3,391,455
-249,379
-7% -$126K 0.15% 45
2025
Q1 		$2.27M Sell
3,640,834
-48,777
-1% -$58.6K 0.21% 49
2024
Q4 		$6.16M Sell
3,689,611
-146,965
-4% -$226K 0.43% 42
2024
Q3 		$6.98M Sell
3,836,576
-199,875
-5% -$743K 0.41% 41
2024
Q2 		$24.3M Sell
4,036,451
-290,058
-7% -$3.57M 1.47% 28
2024
Q1 		$48.2M Buy
4,326,509
+667,245
+18% +$9.37M 1.77% 18
2023
Q4 		$54.5M Buy
3,659,264
+2,375,975
+185% +$22.5M 1.95% 13
2023
Q3 		$6.16M Hold
1,283,289
– – 0.29% 51
2023
Q2 		$9.64M Buy
1,283,289
+696,312
+119% +$4.56M 0.37% 50
2023
Q1 		$2.65M Sell
586,977
-20,493
-3% -$155K 0.12% 64
2022
Q4 		$6.85M Sell
607,470
-144,627
-19% -$1.62M 0.28% 50
2022
Q3 		$7.2M Sell
752,097
-14,700
-2% -$171K 0.28% 55
2022
Q2 		$6.2M Sell
766,797
-5,600
-0.7% -$61K 0.24% 57
2022
Q1 		$13.1M Sell
772,397
-9,700
-1% -$166K 0.41% 50
2021
Q4 		$16.8M Sell
782,097
-82,338
-10% -$3.55M 0.38% 49
2021
Q3 		$63.8M Sell
864,435
-49,600
-5% -$3.31M 1.11% 29
2021
Q2 		$50M Sell
914,035
-64,565
-7% -$3.86M 0.74% 41
2021
Q1 		$72.2M Buy
978,600
+18,200
+2% +$1.43M 1.02% 36
2020
Q4 		$82.8M Buy
960,400
+553,000
+136% +$33.3M 1% 33
2020
Q3 		$15.4M Buy
+407,400
New +$16M 0.28% 59

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Redmile Group's ALXO Position: Q1 2026 in Review

Redmile Group increased its ALX Oncology (ALXO) stake by 144% in Q1 2026, buying an estimated $8.95M and bringing the position to 7,964,188 shares worth $16M. The position accounts for 1.06% of the portfolio, ranked #15.

Redmile Group first reported a position in ALXO in Q3 2020 and has held it in 23 quarters since. The position peaked at $82.8M in Q4 2020. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Redmile Group held 7,964,188 shares of ALX Oncology worth $16M as of Q1 2026.
  • Redmile Group bought 4,699,470 ALX Oncology shares in Q1 2026, an estimated $8.95M.
  • ALX Oncology made up 1.06% of Redmile Group's portfolio in Q1 2026, its #15 holding.
  • Redmile Group first reported a position in ALX Oncology in Q3 2020 and has held it in 23 quarters since.
  • Redmile Group's ALX Oncology position peaked at $82.8M in Q4 2020.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.